Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Wayne L Furman. (2021) Monoclonal Antibody Therapies for High Risk Neuroblastoma. Biologics: Targets and Therapy 15, pages 205-219.
Read now
Read now
Michael W. Bishop, Paul R. Hutson, Jacquelyn A. Hank, Paul M. Sondel, Wayne L. Furman, Michael M. Meagher, Fariba Navid & Victor M. Santana. (2020) A Phase 1 and pharmacokinetic study evaluating daily or weekly schedules of the humanized anti-GD2 antibody hu14.18K322A in recurrent/refractory solid tumors. mAbs 12:1.
Read now
Read now
Michelle E Keyel & C Patrick Reynolds. (2019) Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy. Biologics: Targets and Therapy 13, pages 1-12.
Read now
Read now
Sascha Troschke-Meurer, Nikolai Siebert, Madlen Marx, Maxi Zumpe, Karoline Ehlert, Oliver Mutschlechner, Hans Loibner, Ruth Ladenstein & Holger N. Lode. (2019) Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2. OncoImmunology 8:12.
Read now
Read now
Articles from other publishers (42)
Holger N. Lode, Karoline Ehlert, Stephanie Huber, Sascha Troschke-Meurer, Nikolai Siebert, Maxi Zumpe, Hans Loibner & Ruth Ladenstein. (2023) Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study. British Journal of Cancer 129:11, pages 1780-1786.
Crossref
Crossref
François Sevrin, Hélène Kolesnikov‐Gauthier, Olivier Cougnenc, Emilie Bogart, Gudrun Schleiermacher, Frederic Courbon, Marion Gambart, Anne‐Laure Giraudet, Nadège Corradini, Jean‐Noël Badel, Erwann Rault, Aurore Oudoux, Marie Cécile Le Deley, Dominique Valteau‐Couanet & Anne‐Sophie Defachelles. (2023)
Phase II study of
131
I‐metaiodobenzylguanidine with 5 days of topotecan for refractory or relapsed neuroblastoma: Results of the French study MIITOP
. Pediatric Blood & Cancer.
Crossref
Crossref
Aleksandra Wieczorek, Urszula Żebrowska, Marek Ussowicz, Agnieszka Sokół, Marzena Stypińska, Bożenna Dembowska-Bagińska, Katarzyna Pawińska-Wąsikowska & Walentyna Balwierz. (2023) Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory/Relapsed Settings—Real-World Data. Journal of Clinical Medicine 12:16, pages 5252.
Crossref
Crossref
N. S. Ivanov, D. Yu. Kachanov & T. V. Shamanskaya. (2023) Neuroblastoma chemoimmunotherapy: current results and application prospects. Russian Journal of Pediatric Hematology and Oncology 10:2, pages 77-91.
Crossref
Crossref
Marjolein C Stip, Mitchell Evers, Maaike Nederend, Chilam Chan, Karli R Reiding, Mirjam J Damen, Albert J R Heck, Sofia Koustoulidou, Ruud Ramakers, Gerard C Krijger, Remmert de Roos, Edouard Souteyrand, Annelisa M Cornel, Miranda P Dierselhuis, Marco Jansen, Mark de Boer, Thomas Valerius, Geert van Tetering, Jeanette H W Leusen & Friederike Meyer-Wentrup. (2023) IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models. Journal for ImmunoTherapy of Cancer 11:7, pages e006948.
Crossref
Crossref
Holger N. Lode, Ruth Ladenstein, Sascha Troschke-Meurer, Linda Struppe, Nikolai Siebert, Maxi Zumpe, Karoline Ehlert, Stefanie Huber, Evgenia Glogova, Patrick Hundsdoerfer, Angelika Eggert, Anna Zaniewska-Tekieli, Walentyna Balwierz & Aleksandra Wieczorek. (2023) Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy. Cancers 15:13, pages 3364.
Crossref
Crossref
Nikolai Siebert, Maxi Zumpe, Christian Heinrich Schwencke, Simon Biskupski, Sascha Troschke-Meurer, Justus Leopold, Alexander Zikoridse & Holger N. Lode. (2023) Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta. Cancers 15:13, pages 3317.
Crossref
Crossref
Tim Flaadt, Ruth L. Ladenstein, Martin Ebinger, Holger N. Lode, Helga Björk Arnardóttir, Ulrike Poetschger, Wolfgang Schwinger, Roland Meisel, Friedhelm R. Schuster, Michaela Döring, Peter F. Ambros, Manon Queudeville, Jörg Fuchs, Steven W. Warmann, Jürgen Schäfer, Christian Seitz, Patrick Schlegel, Ines B. Brecht, Ursula Holzer, Tobias Feuchtinger, Thorsten Simon, Johannes H. Schulte, Angelika Eggert, Heiko-Manuel Teltschik, Toni Illhardt, Rupert Handgretinger & Peter Lang. (2023) Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial. Journal of Clinical Oncology 41:17, pages 3135-3148.
Crossref
Crossref
Tami K. Omdahl, Janelle L. Stenzel, Marsha L. Pike, Patricia M. Conlon, Tracy A. Barry, Tanya M. Brown, Kari L. Cambern, Kadi M. Davis, Kelly A. Fjerstad, Kevin K. Graner, Alexis K. Kuhn, Alison P. Larson, Amir B. Orandi, Emily L. Smith, Scott A. Soefje & Alan M. Janssen. (2023) Pediatric Chemotherapy Infusions in Outpatient Examination Rooms: A Novel Patient Care Approach. Journal of Pediatric Hematology/Oncology Nursing 40:3, pages 195-202.
Crossref
Crossref
Karsten Nysom, Andrea Gomez Morad, Margarida Simão Rafael, Judith Zier, Araz Marachelian, Tanya Watt & Daniel A. Morgenstern. (2023) Pain mitigation and management strategies for anti‐GD2 infusions: An expert consensus. Pediatric Blood & Cancer 70:5.
Crossref
Crossref
Shan Liu, Weimin Yin, Yaobin Lin, Sihan Huang, Shufang Xue, Gaoyuan Sun & Chengyi Wang. (2023) Metastasis pattern and prognosis in children with neuroblastoma. World Journal of Surgical Oncology 21:1.
Crossref
Crossref
Niklas Abele, Soenke Langner, Ute Felbor, Holger Lode & Norbert Hosten. (2023) Quantitative Diffusion-Weighted MRI of Neuroblastoma. Cancers 15:7, pages 1940.
Crossref
Crossref
Aleksandra Wieczorek, Anna Zaniewska-Tekieli, Karoline Ehlert, Katarzyna Pawinska-Wasikowska, Walentyna Balwierz & Holger Lode. (2023) Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma. Frontiers in Oncology 13.
Crossref
Crossref
Julia Balaguer, Laura García Hidalgo, Raquel Hladun, Catalina Márquez Vega & Vanesa Pérez Alonso. (2022) Recent Evidence-Based Clinical Guide for the Use of Dinutuximab Beta in Pediatric Patients with Neuroblastoma. Targeted Oncology 18:1, pages 77-93.
Crossref
Crossref
Irena Horwacik. (2022) The Extracellular Matrix and Neuroblastoma Cell Communication—A Complex Interplay and Its Therapeutic Implications. Cells 11:19, pages 3172.
Crossref
Crossref
Sofia Ahrens, Birgit Appl, Magdalena Trochimiuk, Charlotte Dücker, Gemma Feixas Serra, Albert Oliver Grau, Konrad Reinshagen & Laia Pagerols Raluy. (2022) Kigelia africana inhibits proliferation and induces cell death in stage 4 Neuroblastoma cell lines. Biomedicine & Pharmacotherapy 154, pages 113584.
Crossref
Crossref
Aleksandra Wieczorek, Carla Manzitti, Alberto Garaventa, Juliet Gray, Vassilios Papadakis, Dominique Valteau-Couanet, Katarzyna Zachwieja, Ulrike Poetschger, Ingrid Pribill, Stefan Fiedler, Ruth Ladenstein & Holger N. Lode. (2022) Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials. Cancers 14:8, pages 1919.
Crossref
Crossref
Vassilios Papadakis, Charikleia Kelaidi, Kalliopi Zisaki, Kondylia Antoniadi, Georgios Pitsoulakis & Sophia Polychronopoulou. (2021) Dinutuximab beta‐related severe neurotoxicity: Resolution with the use of plasmapheresis. Pediatric Blood & Cancer 69:4.
Crossref
Crossref
Thorsten Simon, Barbara Hero, Matthias Fischer, Holger N. Lode & Angelika Eggert. 2020. Kompendium Internistische Onkologie. Kompendium Internistische Onkologie
1
14
.
J. Sebastian Temme & Jeffrey C. Gildersleeve. 2022. Glycan Microarrays. Glycan Microarrays
67
87
.
Stefano Mastrangelo, Serena Rivetti, Silvia Triarico, Alberto Romano, Giorgio Attinà, Palma Maurizi & Antonio Ruggiero. (2021) Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients. International Journal of Molecular Sciences 22:23, pages 12648.
Crossref
Crossref
Giuseppe Barone, Ailish Barry, Francisco Bautista, Bénédicte Brichard, Anne-Sophie Defachelles, Fiona Herd, Carla Manzitti, Dirk Reinhardt, Pedro M. Rubio, Aleksandra Wieczorek & Max M. van Noesel. (2021) Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance. Pediatric Drugs 23:6, pages 537-548.
Crossref
Crossref
I. V. Kazantsev, A. G. Gevorgyan, T. V. Yukhta, D. A. Drozdovskaya, P. S. Tolkunova, E. V. Goncharova, A. V. Kozlov, M. S. Golenkova, A. N. Galimov, O. I. Bogdanova, Yu. A. Punanov, A. D. Kulagin & L. S. Zubarovskaya. (2021) Immunotherapy by anti-GD2 antibodies in patients with primary high-risk neuroblastoma, primary resistant and relapsed disease: Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, First Pavlov State Medical University of St. Petersburg experience. Russian Journal of Pediatric Hematology and Oncology 8:3, pages 14-29.
Crossref
Crossref
Christian Martin Seitz, Tim Flaadt, Markus Mezger, Anne-Marie Lang, Sebastian Michaelis, Marie Katz, Desireé Syring, Alexander Joechner, Armin Rabsteyn, Nikolai Siebert, Sascha Troschke-Meurer, Maxi Zumpe, Holger N. Lode, Sile F. Yang, Daniel Atar, Anna-Sophia Mast, Sophia Scheuermann, Florian Heubach, Rupert Handgretinger, Peter Lang & Patrick Schlegel. (2021) Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment. Frontiers in Immunology 12.
Crossref
Crossref
Nadiya Bayeva, Erin Coll & Olga Piskareva. (2021) Differentiating Neuroblastoma: A Systematic Review of the Retinoic Acid, Its Derivatives, and Synergistic Interactions. Journal of Personalized Medicine 11:3, pages 211.
Crossref
Crossref
Thomas Blom, Roosmarijn Lurvink, Leonie Aleven, Maarten Mensink, Tom Wolfs, Miranda Dierselhuis, Natasha van Eijkelenburg, Kathelijne Kraal, Max van Noesel, Martine van Grotel & Godelieve Tytgat. (2021) Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients. Frontiers in Oncology 10.
Crossref
Crossref
Thorsten Simon, Barbara Hero, Matthias Fischer, Holger N. Lode & Angelika Eggert. 2020. Kompendium Internistische Onkologie. Kompendium Internistische Onkologie
1
14
.
Filiz Cicek, Sascha Troschke-Meurer, Kiraz Ceylan, Luciana J. Jahns, Maxi Zumpe, Nikolai Siebert, Karoline Ehlert & Holger N. Lode. (2020) Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy. Frontiers in Pediatrics 8.
Crossref
Crossref
Yan Su, Lijun Wang, Qian Zhao, Zhixia Yue, Wen Zhao, Xisi Wang, Chao Duan, Mei Jin, Dawei Zhang, Shenglan Chen, Jianfeng Yin, Lihua Qiu, Xianfeng Cheng, Zhong Xu & Xiaoli Ma. (2020)
Implementation of the plasma
MYCN
/
NAGK
ratio to detect
MYCN
amplification in patients with neuroblastoma
. Molecular Oncology 14:11, pages 2884-2893.
Crossref
Crossref
T. V. Shamanskaya, N. A. Andreeva, D. T. Utalieva & D. Yu. Kachanov. (2020) Anti-GD2 immunotherapy with the chimeric antibody ch14.18 for high-risk neuroblastoma. Pediatric Hematology/Oncology and Immunopathology 19:3, pages 173-178.
Crossref
Crossref
I. V. Kazantsev, A. G. Gevorgyan, T. V. Yukhta, P. S. Tolkunova, D. A. Zvyagintseva, A. V. Kozlov, M. S. Golenkova, E. V. Babenko, P. S. Kuga, A. N. Shvetsov, I. Yu. Nikolaev, E. V. Morozova, S. A. Safonova, Yu. A. Punanov, L. S. Zubarovskaya & B. V. Afanasyev. (2020) The complex intensive therapy regimen as curative therapy in patients with primary-resistant and relapsed neuroblastoma: R.M. Gorbacheva Memorial Institute for Children Oncology, Hematology and Transplantation experience. Pediatric Hematology/Oncology and Immunopathology 19:2, pages 129-140.
Crossref
Crossref
Maxim Sorokin, Irina Kholodenko, Daniel Kalinovsky, Tatyana Shamanskaya, Igor Doronin, Dmitry Konovalov, Aleksei Mironov, Denis Kuzmin, Daniil Nikitin, Sergey Deyev, Anton Buzdin & Roman Kholodenko. (2020) RNA Sequencing-Based Identification of Ganglioside GD2-Positive Cancer Phenotype. Biomedicines 8:6, pages 142.
Crossref
Crossref
Karoline Ehlert, Ina Hansjuergens, Andreas Zinke, Sylke Otto, Nikolai Siebert, Guenter Henze & Holger Lode. (2020) Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma. Journal for ImmunoTherapy of Cancer 8:1, pages e000540.
Crossref
Crossref
I. V. Proleskovskaya, N. E. Konoplya & O. I. Bydanov. (2020) Treatment of relapse/progression of the disease in patients with neuroblastoma in the Republic of Belarus over a 20-year period: a cohort study. Russian Journal of Pediatric Hematology and Oncology 6:4, pages 40-47.
Crossref
Crossref
Dominique Valteau-Couanet, Véronique Minard-Colin & Claudia Pasqualini. (2020) Neuroblastome de haut risque. médecine/sciences 35:12, pages 997-1000.
Crossref
Crossref
Brian Hutzen, Siddhi Nath Paudel, Meisam Naeimi Kararoudi, Kevin A. Cassady, Dean A. Lee & Timothy P. Cripe. (2019) Immunotherapies for pediatric cancer: current landscape and future perspectives. Cancer and Metastasis Reviews 38:4, pages 573-594.
Crossref
Crossref
Chi Zhang, Xilin Xiong, Yang Li, Ke Huang, Ling Liu, Xiaomin Peng & Wenjun Weng. (2019) Cytokine‑induced killer cells/natural killer cells combined with anti‑GD2 monoclonal antibody increase cell death rate in neuroblastoma SK‑N‑SH cells. Oncology Letters.
Crossref
Crossref
Irina V. Kholodenko, Daniel V. Kalinovsky, Elena V. Svirshchevskaya, Igor I. Doronin, Maria V. Konovalova, Alexey V. Kibardin, Tatyana V. Shamanskaya, Sergey S. Larin, Sergey M. Deyev & Roman V. Kholodenko. (2019) Multimerization through Pegylation Improves Pharmacokinetic Properties of scFv Fragments of GD2-Specific Antibodies. Molecules 24:21, pages 3835.
Crossref
Crossref
Alessandra Marrella, Alessandra Dondero, Maurizio Aiello, Beatrice Casu, Daniel Olive, Stefano Regis, Cristina Bottino, Daniela Pende, Raffaella Meazza, Guido Caluori, Roberta Castriconi & Silvia Scaglione. (2019) Cell-Laden Hydrogel as a Clinical-Relevant 3D Model for Analyzing Neuroblastoma Growth, Immunophenotype, and Susceptibility to Therapies. Frontiers in Immunology 10.
Crossref
Crossref
Julie Voeller & Paul M. Sondel. (2019) Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma. Journal of Pediatric Hematology/Oncology 41:3, pages 163-169.
Crossref
Crossref
Nikolai Siebert, Sascha Troschke-Meurer, Madlen Marx, Maxi Zumpe, Karoline Ehlert, Juliet Gray, Alberto Garaventa, Carla Manzitti, Shifra Ash, Thomas Klingebiel, James Beck, Victoria Castel, Dominique Valteau-Couanet, Hans Loibner, Ruth Ladenstein & Holger Lode. (2018) Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial. Cancers 10:10, pages 387.
Crossref
Crossref
M. Fevzi Ozkaynak, Andrew L. Gilman, Wendy B. London, Arlene Naranjo, Mitchell B. Diccianni, Sheena C. Tenney, Malcolm Smith, Karen S. Messer, Robert Seeger, C. Patrick Reynolds, L. Mary Smith, Barry L. Shulkin, Marguerite Parisi, John M. Maris, Julie R. Park, Paul M. Sondel & Alice L. Yu. (2018) A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931. Frontiers in Immunology 9.
Crossref
Crossref